Table 2. Induction regimens administered to 1% or more of patients in either squamous or nonsquamous cohorts, by histology and overall.
|
Induction regimen* |
Squamous (n = 436) |
Nonsquamous (n = 1,578) |
All Patients (N = 2,014) |
|---|---|---|---|
| Carboplatin+pemetrexed | 3 (0.7) | 405 (25.7) | 408 (20.3) |
| Carboplatin+paclitaxel | 164 (37.6) | 220 (13.9) | 384 (19.1) |
| Carboplatin+bevacizumab+pemetrexed | 0 | 252 (16.0) | 252 (12.5) |
| Carboplatin+bevacizumab+paclitaxel | 4 (0.9) | 171 (10.8) | 175 (8.7) |
| Carboplatin+ nab-paclitaxel | 92 (21.1) | 37 (2.3) | 129 (6.4) |
| Erlotinib | 13 (3.0) | 58 (3.7) | 71 (3.5) |
| Carboplatin+gemcitabine | 51 (11.7) | 16 (1.0) | 67 (3.3) |
| Pemetrexed | 2 (0.5) | 64 (4.1) | 66 (3.3) |
| Carboplatin+docetaxel | 21 (4.8) | 38 (2.4) | 59 (2.9) |
| Cisplatin+pemetrexed | 0 | 44 (2.8) | 44 (2.2) |
| Docetaxel | 6 (1.4) | 24 (1.5) | 30 (1.5) |
| Gemcitabine | 8 (1.8) | 21 (1.3) | 29 (1.4) |
| Carboplatin+etoposide | 1 (0.2) | 25 (1.6) | 26 (1.3) |
| Cisplatin+etoposide | 6 (1.4) | 15 (1.0) | 21 (1.0) |
| Carboplatin+bevacizumab+docetaxel | 0 | 16 (1.0) | 16 (0.8) |
| Bevacizumab+pemetrexed | 0 | 16 (1.0) | 16 (0.8) |
| Cisplatin+gemcitabine | 11 (2.5) | 6 (0.4) | 17 (0.8) |
| Carboplatin+paclitaxel/nab-paclitaxel | 10 (2.3) | 6 (0.4) | 16 (0.8) |
| Vinorelbine | 7 (1.6) | 8 (0.5) | 15 (0.7) |
| Paclitaxel | 6 (1.4) | 11 (0.7) | 17 (0.8) |
| nab-Paclitaxel | 5 (1.2) | 5 (0.3) | 10 (0.5) |
| Other regimens† | 26 (6.0) | 120 (7.6) | 146 (7.2) |
Data are n (%).
Abbreviation: nab-paclitaxel, albumin-bound paclitaxel particles
*Induction regimen includes patients who received induction therapy only or patients who received induction followed by continuation maintenance.
†”Other” regimens were those received by <1% of patients in each cohort (squamous or nonsquamous)